Merck KGaA, Darmstadt, Germany receives recommendation for approval in 21 EU countries for the new formulation of Euthyrox®
- German Federal Institute for Drugs and Medical Devices (BfArM) recommends new formulation of Euthyrox® for approval in 21 EU countries
- BfArM is acting as a representative of all 21 EU countries involved in the EU worksharing procedure
Darmstadt, Germany, July 26, 2018 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the German Federal Institute for Drugs and Medical Devices has recommended to approve the company’s new formulation of Euthyrox® (levothyroxine) in 21 EU countries. National approvals will be issued following this recommendation.
"The tighter specification of the active ingredient in the new formulation of Euthyrox® aims to help patients have better control over their individual levothyroxine dosage,” said Steven Hildemann, Global Chief Medical Officer at the Biopharma business of Merck KGaA, Darmstadt, Germany. “Following the positive recommendation from BfArM, Merck KGaA, Darmstadt, Germany will continue to collaborate closely with local Health Authorities, health care professionals and patient groups in preparation for the roll out of the new formulation in the 21 countries. Together with the respective stakeholders, and in full compliance with the local regulations, we aim to ensure that patients are appropriately informed. Therefore it is our first priority to support physicians and help them provide their patients with the best possible transition to the new formulation of Euthyrox®.”
The German BfArM decision to recommend the approval of the new formulation of Euthyrox® across 21 EU states was based on a study demonstrating bioequivalence between the old and new formulations.
Levothyroxine is a synthetically produced hormone that corresponds to the natural thyroid hormone Thyroxin (T4). It is used to treat hypothyroidism, goiter and to suppress TSH in the post-treatment of differentiated thyroid cancer.
The new formulation came at the request of several health authorities worldwide. It was introduced in France in March 2017 and Switzerland in April 2018. Turkish authorities have approved the new formulation and Merck KGaA, Darmstadt, Germany expects to launch the medicine there in the course of 2018.
For thyroid drugs a small dosage variation might impact the patient’s thyroid balance. Prescribing doctors are therefore encouraged to monitor patients closely when prescribing the new formulation and to adjust the individual dosage if medically required. Along with the Health Authorities Merck KGaA, Darmstadt, Germany recommends that all patients do not switch or stop their treatment without medical advice and refer to their prescribing physician to potentially adjust the medication dose to their individual need during the transition phase.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.